Results 41 to 50 of about 21,074 (263)
Clinical Pharmacology &Therapeutics, EarlyView.Orforglipron is an orally administered, small‐molecule glucagon‐like peptide‐1 receptor agonist in clinical development for the treatment of type 2 diabetes and obesity. Orforglipron is a substrate of CYP3A4, organic anion transporting polypeptides (OATPs) 1B/1B3, and P‐glycoprotein (P‐gp); however, precipitants commonly used to define these mechanisms
Bridget L. Morse +7 more
wiley +1 more source
Fasting GLP-1 Levels in Women with PCOS and CAH
Acta Medica BulgaricaPolycystic ovarian syndrome (PCOS) is the most prevalent condition associated with increased androgens, but some rare diseases, e.g., congenital adrenal hyperplasia (CAH), should also be considered in the differential diagnosis of hyperandrogenemia.
Robeva R. +3 more
doaj +1 more source
Glucagon Like Peptide 1 and Evidence Around Diabetes Specific Nutrition
World Nutrition, 2019 There has been significant research and development in pharmaco-therapeutic molecules for management of type 2 diabetes mellitus (T2DM). Diabetes specific nutrition intervention & newer incretin-based therapies have gained a lot of attention.
ANSHU JOSHI, SAMEER RAO, GANESH KADHE
doaj +1 more source
Clinical Pharmacology &Therapeutics, EarlyView.Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are increasingly prescribed for type 2 diabetes and weight management. However, conflicting evidence from preclinical, clinical, and pharmacovigilance studies suggests potential neuropsychiatric effects.
Maria J. Alfonso Arvez +6 more
wiley +1 more source
Equine Veterinary Journal, EarlyView.Abstract Background Treatment with the sodium‐glucose co‐transporter 2 (SGLT2) inhibitor canagliflozin in insulin dysregulated (ID) horses has shown promising results in randomised clinical trials. Larger field studies are needed to further evaluate treatment responses and potential adverse effects under real‐world conditions.
Moa Hällbom +3 more
wiley +1 more source
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Cells, 2023 Glucagon-like peptide-1 receptor agonists (GLP1RA) have been transformative for patients and clinicians in treating type-2 diabetes and obesity. Drugs of this class, the bioavailability of which is continuously improving, enable weight loss and control ...
Sydney S. Wilbon, Mikhail G. Kolonin
doaj +1 more source
A New Vista of Opportunity in Diabetes Management: Natural Product‐Based β‐cell Preservation
Food Chemistry International, EarlyView.Preserving functional β‐cells via natural products offers promising strategy for diabetes treatment. ABSTRACT A defining characteristic of diabetes is β‐cell failure, in which β‐cells cannot modulate insulin secretion to compensate for escalating insulin resistance, pushing forward disease development.
Yi‐San Lee +4 more
wiley +1 more source
Food Safety and Health, EarlyView.Circadian rhythm disruption impairs metabolic regulation, appetite control, and vascular function, promoting obesity and cardiovascular diseases. Evidence highlights a bidirectional relationship where metabolic disorders further disturb circadian timing.
Ghizal Fatima +4 more
wiley +1 more source
Diabetes, Metabolic Syndrome and Obesity, 2018 Anne J Kugler,1 Michael L Thiman2 1Department of Pharmacy Practice and Administration, Western University of Health Sciences College of Pharmacy, Pomona, CA, USA; 2Department of Clinical and Administrative Pharmacy, University of Georgia College of ...
Kugler AJ, Thiman ML
doaj